JPRN-UMIN000023006CompletedPhase 4
sefullness of infliximab as a second tumor necrosis factor inhibitor in patients with rheumatoid arthritis with inadequate response to tumor necrosis factor inhibitor - IFX-2nd
Osaka City University Graduate School of Medicine0 sites1 target enrollmentStarted: July 15, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 1
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 85years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) The patients with inadequate response to IFX after 6-weekloading administration 2) The patients with arthritic condition other than Ra 3) The patients who is planned to undergo surgery 4) Patients with allergy to IFX 5) Patients who is pregnant or lactate 6)patients who have received IFX administration 7) Those who are not approved to be eligible to this study by corresponding researcher or co-researchers
Investigators
Similar Trials
Completed
Not Applicable
Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritisRheumatoid arthritisJPRN-UMIN000020799Hokkaido University Hospital, Medicine II30
Completed
Not Applicable
Effectiveness of infliximab (tumor necrotising factor-alpha antagonist) in the treatment of late-onset depressive spectrum disorder in patients of 60 years and aboveDepressionISRCTN65900535eiden University Medical Center (LUMC) (The Netherlands)50
Completed
Phase 2
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related CachexiaCachexiaPancreatic NeoplasmsNCT00060502Centocor, Inc.73
Completed
Phase 2
Infliximab in Treating Patients With Myelodysplastic SyndromeMyelodysplastic SyndromesNCT00074074European Organisation for Research and Treatment of Cancer - EORTC46
Completed
Not Applicable
Efficacy and safety of the biosimilar Infliximab in the patients with ulcerative colitisulcerative colitisJPRN-UMIN000027465niversity of Toyama20